Advertisement
UK markets close in 40 minutes
  • FTSE 100

    7,875.81
    +27.82 (+0.35%)
     
  • FTSE 250

    19,396.04
    +55.90 (+0.29%)
     
  • AIM

    744.39
    +1.27 (+0.17%)
     
  • GBP/EUR

    1.1675
    +0.0008 (+0.07%)
     
  • GBP/USD

    1.2452
    -0.0004 (-0.04%)
     
  • Bitcoin GBP

    51,281.26
    +1,596.51 (+3.21%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • S&P 500

    5,046.14
    +23.93 (+0.48%)
     
  • DOW

    38,016.47
    +263.16 (+0.70%)
     
  • CRUDE OIL

    82.56
    -0.13 (-0.16%)
     
  • GOLD FUTURES

    2,387.60
    -0.80 (-0.03%)
     
  • NIKKEI 225

    38,079.70
    +117.90 (+0.31%)
     
  • HANG SENG

    16,385.87
    +134.03 (+0.82%)
     
  • DAX

    17,822.11
    +52.09 (+0.29%)
     
  • CAC 40

    8,029.79
    +48.28 (+0.60%)
     

Could This Unknown Stock Beat Moderna in 2023?

Vaxart (NASDAQ: VXRT) might just be gearing up to steal coronavirus vaccine market share from Moderna (NASDAQ: MRNA) in the next couple of years, making its investors wealthy in the process. The biotech's vaccine tablets could have a few advantages that Moderna's shots don't, including one in particular, that might be a public health holy grail at the moment. For Vaxart's stock to beat Moderna's next year, two things need to happen.